Wall Street analyst estimates for Tivic Health Systems, Inc. (TIVC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-08-17 | $-408.00 | ||
| 2025-11-14 | $-1.97 | $-102.00 | +98.1% |
| 2025-08-14 | $-2.19 | $-102.00 | +97.9% |
| 2025-05-15 | $-2.52 | $-119.00 | +97.9% |
| 2025-03-21 | $-1.54 | $-1.19 | -29.7% |
| 2025-03-20 | $-0.90 | $-85.00 | +98.9% |
| 2024-11-14 | $-3.91 | $-119.00 | +96.7% |
| 2024-08-14 | $-5.44 | $-136.00 | +96.0% |
Valuation Ratios
| Price / Book | 0.07 |
| EV / EBITDA | -0.50 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $420000 | $860000 | $1.2M | $1.8M | $1.2M | $780000 | $382000 |
| Cost of Revenue | $709000 | $1.1M | $1.3M | $1.5M | $889000 | $778000 | $5000 |
| Gross Profit | -$289000 | -$225000 | -$129000 | $299000 | $287000 | $2000 | -$5000 |
| Research & Development | $990000 | $659000 | $878000 | $1.7M | $1.7M | $1.3M | $3.1M |
| Selling, General & Admin | $2.4M | $2.3M | $4.6M | $8.7M | $6.9M | $4.3M | $5.6M |
| Operating Expenses | $3.4M | $3.0M | $5.5M | $10.4M | $8.5M | $5.7M | $7.9M |
| Operating Income | -$3.6M | -$3.2M | -$5.6M | -$10.1M | -$8.2M | -$5.7M | -$7.9M |
| EBITDA | -$3.7M | -$3.2M | -$6.6M | -$9.9M | -$8.1M | -$5.3M | -$7.8M |
| Interest Expense | $443000 | $423000 | $1.8M | 0 | 0 | 0 | $146000 |
| Pre-tax Income | -$4.1M | -$3.6M | -$8.5M | -$10.1M | -$8.2M | -$5.7M | -$8.0M |
| Income Tax | $2000 | 0 | $1000 | 0 | 0 | 0 | 0 |
| Net Income | -$4.1M | -$3.6M | -$8.5M | -$10.1M | -$8.2M | -$5.7M | -$8.9M |
| EPS | $-180.36 | $-177.01 | $-243.16 | $-104.37 | $-176.72 | $-19.67 | $-7.84 |
| EPS (Diluted) | $-180.35 | $-177.01 | $-243.15 | $-104.37 | $-176.72 | $-19.67 | $-7.84 |
| Shares Outstanding (Diluted) | $23000 | $23032 | $34933 | $96730 | $46650 | $287.4M | $287370 |
Price
| Price | $0.26 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Related companies: BBLG · BJDX · CNTX · HSCS · MRAI · NUWE · PETV
Explore sector: Healthcare · Medical - Specialties
More sections of TIVC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks